Dr Charmaine Gittleson: Ledger

Stories naming Dr Charmaine Gittleson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Chair	Percheron Therapeutics	Biotech Dispatch (1 Sep 2026), Biotech Dispatch (10 Aug 2026)

Unnamed stage $2.3m

Percheron raises $2.3 million to fully fund Vanderbilt AML trial

Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.

Biotech Dispatch 1 Sep 2026 Percheron Therapeutics Blue Ocean Equities Cygnet Capital Dr Charmaine Gittleson Dr Michael Baker

Dr Charmaine Gittleson

Roles

Coverage

Percheron raises $2.3 million to fully fund Vanderbilt AML trial

Percheron turns to former Arovella chief Michael Baker for next phase of HMBD-002 development